Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 39.40
Change Today -0.50 / -1.25%
Volume 66.0K
HDST On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Tel Aviv
As of 10:24 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

hadasit bio holdings ltd (HDST) Snapshot

Open
$39.90
Previous Close
$39.90
Day High
$39.90
Day Low
$38.90
52 Week High
11/2/14 - $94.00
52 Week Low
06/22/15 - $30.50
Market Cap
13.8M
Average Volume 10 Days
84.5K
EPS TTM
$-0.50
Shares Outstanding
35.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HADASIT BIO HOLDINGS LTD (HDST)

Related News

No related news articles were found.

hadasit bio holdings ltd (HDST) Related Businessweek News

No Related Businessweek News Found

hadasit bio holdings ltd (HDST) Details

Hadasit Bio-Holdings, Ltd., through its subsidiaries, is engaged in the research and development in medical and biotechnology fields in Israel. It is involved in the development of Prozumab, a monoclonal antibody that is in late-stage preclinical development for the treatment of inflammatory bowel disease, ulcerative colitis, rheumatoid arthritis, and other autoimmune diseases. The company is also engaged in the development of autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions, such as graft versus host disease, solid organ transplant rejection, Crohn's disease, and other autoimmune and inflammatory disorders. In addition, it develops Colon-MarCarePlex, a diagnostic kit for the early diagnosis and precancerous diagnosis of colorectal cancer using a simple molecular blood test; and mCRC-Strat, a personalized medicine assay predicting responsiveness to anti EGFR therapy. The company was founded in 2005 and is based in Jerusalem, Israel.

Founded in 2005

hadasit bio holdings ltd (HDST) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: 381.0K
Compensation as of Fiscal Year 2013.

hadasit bio holdings ltd (HDST) Key Developments

Hadasit Bio-Holdings, Ltd., Annual General Meeting, May 26, 2015

Hadasit Bio-Holdings, Ltd., Annual General Meeting, May 26, 2015., at 10:00 Israel Standard Time.

Hadasit Bio-Holdings, Ltd. Auditor Raises 'Going Concern' Doubt

Hadasit Bio-Holdings, Ltd. filed its Annual on Mar 23, 2015 for the period ending Dec 31, 2014. In this report its auditor, Brightman Almagor Zohar & Co, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Hadasit Bio-Holdings, Ltd., Special/Extraordinary Shareholders Meeting, Mar 04, 2015

Hadasit Bio-Holdings, Ltd., Special/Extraordinary Shareholders Meeting, Mar 04, 2015., at 10:00 Israel Standard Time.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HDST:IT 39.40 -0.50

HDST Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HDST.
View Industry Companies
 

Industry Analysis

HDST

Industry Average

Valuation HDST Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HADASIT BIO HOLDINGS LTD, please visit www.hbl.co.il. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.